Amylyx Q3 Loss Widens to $45.5M as Avexitide Launch Prep Drives Spend; $768.1M Cash
AMLX has more than doubled off its 52-week low of $10.83.
Summary
Amylyx posted a $45.5M Q3 loss as avexitide launch preparation drove R&D and SG&A higher, backed by $768.1M in cash and securities. It also locked in commercial avexitide supply through Bachem and a Polypeptide term sheet with a $30M pre-payment.
Key Events · Earnings and Guidance · AMLX
-
Q3 Loss Widens on Launch Prep
Net loss was $45.5M ($0.38 per share) versus $34.4M ($0.37) in Q3 2025; nine-month loss reached $130.2M.
-
R&D and SG&A Step Up
R&D rose 43% to $28.4M on the LUCIDITY/avexitide program; SG&A rose 32% to $21.3M on pre-commercial hiring and marketing.
-
Balance Sheet Funds Launch
Cash, cash equivalents and marketable securities totaled $768.1M at September 30, 2026, following the August offering's $544.6M net proceeds.
-
Commercial Supply Locked In
Signed a five-year Bachem manufacturing agreement and a Polypeptide term sheet requiring a $30M non-refundable capacity reservation pre-payment.
Analysis · AMLX · Life Sciences
The widening loss is the price of launch preparation, not distress. Amylyx's quarterly loss grew to $45.5M ($0.38/share) from $34.4M a year ago, as R&D climbed 43% to $28.4M and SG&A rose 32% to $21.3M on staffing and commercial readiness for avexitide ahead of an NDA submission planned by end-2026. The August offering left $768.1M in cash and securities, enough to fund the potential 2027 launch. What's new is the supply chain build-out: a commercial manufacturing agreement with Bachem and a Polypeptide term sheet carrying a $30M non-refundable capacity pre-payment, which locks in long-term avexitide drug supply but adds fixed obligations. On the legal front, the Shih securities class action is now settled ($6.5M, court-approved September 10, 2026), removing one overhang, though derivative suits remain in settlement talks.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AMLX was trading at $30.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $10.83 to $41.14. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.